Where does Medtronic see opportunities and challenges?

MedtronicTalks

Contenuto fornito da MedtronicTalks and Tom Salemi. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da MedtronicTalks and Tom Salemi o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.

3+ y ago 34:59

MP3•Pagina principale dell'episodio

Fetch error

Hmmm there seems to be a problem fetching this series right now. Last successful fetch was on October 10, 2024 22:11 (1M ago)

What now? This series will be checked again in the next day. If you believe it should be working, please verify the publisher's feed link below is valid and includes actual episode links. You can contact support to request the feed be immediately fetched.

Less than a year into his role as CEO, Geoff Martha and the Medtronic leadership has overseen a significant overhaul of medtech’s largest player. Martha says the company is clearing minor COVID-19 bump and sees an open road for the company to continue to grab share from competitors. Martha details what products are gaining the most traction while also identifying those that still have some ground to gain. We also discuss: -When it may bring its renal denervation project to the FDA -Why the surgical robotic Hugo system will be worth the wait (and why development has taken more than a decade) -Whether or not Medtronic will collaborate more with private equity firms, early-stage incubators and maybe even SPACs? -What will the company’s acquisition strategy look like in 2021. And why. Why the price-cutting for drug-eluting stents may represent an opportunity for Medtronic’s more innovative products.

47 episodi

#Tech #MedtronicTalks #Tom Salemi